Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year Low - What's Next?

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) shares reached a new 52-week low on Monday . The company traded as low as $8.73 and last traded at $8.84, with a volume of 1180879 shares traded. The stock had previously closed at $9.46.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th.

Roivant Sciences Stock Up 2.2 %

The company has a 50 day simple moving average of $10.40 and a 200 day simple moving average of $11.22. The stock has a market cap of $7.04 billion, a price-to-earnings ratio of -65.73 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Activity

In other Roivant Sciences news, Director Sciences Ltd. Roivant bought 16,845,010 shares of Roivant Sciences stock in a transaction on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the acquisition, the director now directly owns 96,650,341 shares of the company's stock, valued at $1,933,006,820. The trade was a 21.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eric Venker sold 434,478 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the transaction, the chief operating officer now directly owns 1,127,290 shares of the company's stock, valued at $12,197,277.80. The trade was a 27.82 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,395,541 shares of company stock worth $15,028,538. Insiders own 7.90% of the company's stock.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd increased its position in Roivant Sciences by 116.3% during the 3rd quarter. XTX Topco Ltd now owns 55,500 shares of the company's stock valued at $640,000 after purchasing an additional 29,842 shares during the period. Public Employees Retirement System of Ohio raised its stake in Roivant Sciences by 15.6% during the third quarter. Public Employees Retirement System of Ohio now owns 154,495 shares of the company's stock worth $1,783,000 after buying an additional 20,868 shares during the last quarter. Barclays PLC lifted its holdings in Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after buying an additional 75,609 shares during the period. M&T Bank Corp bought a new stake in Roivant Sciences during the third quarter valued at $131,000. Finally, Geode Capital Management LLC boosted its position in Roivant Sciences by 23.2% during the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock valued at $89,400,000 after acquiring an additional 1,460,205 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.